NSAIDs-induced small bowel injury
Conditions
Interventions
Polaprezinc
placebo
Sponsors
Division of Gastroenterology,Department of Internal Medicine, Keio University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patients who have taken NSAIDs for more than one month and who will take NSAIDs for one month after enrollment.
Exclusion criteria
Exclusion criteria: 1) The patients with dysphagia. 2) Pregnant or lactating women. 3) The patients who have history of the ileus or stricture or fistula of the intestine. 4) The patients who have Crohn's disease, Behchet's disease. 5) The patient with pacemaker or other medical electronic equipment. 6) The patient who have taken mucoprotective agent or took it within one month before enrollment. 7) The patient who have severe anemia (less than Hb 8.0mg/dl) or a hematemesis or a melena. 8) The patients who have taken antibiotics or took it within one month before enrollment. 9) The patients who have severe hiatal hernia. 10) The patient who take COX-2 inhibitor (celecoxib) only or low-dose aspirin only. 11) The patients who have severe illness. 12) The patients who have history of abdominal operation or radiation therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Capsule endoscopic findings (number of ulcers/erosions and red spots) | — |
Secondary
| Measure | Time frame |
|---|---|
| Laboratory data and subjective symptom | — |
Countries
Japan
Contacts
Public ContactNaoki Hosoe, M.D., Ph.D.
Keio University Division of Gastroenterology
Outcome results
None listed